Patents by Inventor Girish Kumar Jain
Girish Kumar Jain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240009188Abstract: Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Cmax, AUC0-t and/or AUC0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.Type: ApplicationFiled: September 15, 2023Publication date: January 11, 2024Applicant: SLAYBACK PHARMA LLCInventors: Paras P. JAIN, Ajay Kumar SINGH, Keerthi PRIYA, Girish Kumar JAIN, Girish G. KORE, Sandeep JAIN, Hanimi Reddy BAPATU
-
Patent number: 11793809Abstract: Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Cmax, AUC0-t and/or AUC0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.Type: GrantFiled: November 20, 2020Date of Patent: October 24, 2023Assignee: SLAYBACK PHARMA LLCInventors: Paras P. Jain, Ajay Kumar Singh, Keerthi Priya, Girish Kumar Jain, Girish G. Kore, Sandeep Jain, Hanimi Reddy Bapatu
-
Publication number: 20230310460Abstract: The present invention relates to a low dose topical composition comprising triamcinolone acetonide or salt thereof in an amount of less than 250 mcg/gm, its process of preparation and its use for the treating/preventing of various types of skin diseases, preferably atopic dermatitis in infants, children, adults and elderly patients.Type: ApplicationFiled: August 28, 2021Publication date: October 5, 2023Inventors: Sivakumar Venkata Bobba, Amit Manmode, Dhananjay Shinde, Sunil Pophale, Girish Kumar Jain, Shankar Pol
-
Patent number: 11103503Abstract: Solid dispersions of lurasidone or a pharmaceutically acceptable salt thereof are described, as well as pharmaceutical formulations thereof, and methods for making such formulations. Preferably, the solid dispersions are prepared by hot-melt extrusion or spray-drying, and comprise lurasidone with a pharmaceutically acceptable carrier (e.g., hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), or mixtures thereof). The pharmaceutical composition may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Tmax, Cmax, AUC0-t and/or AUC0-infinity) of lurasidone, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.Type: GrantFiled: January 28, 2020Date of Patent: August 31, 2021Assignee: SLAYBACK PHARMA LLCInventors: Paras P. Jain, Ajay Kumar Singh, Praveen Kumar Subbappa, Keerthi Priya, Girish Kumar Jain, Girish G. Kore, Hanimi Reddy Bapatu, Sandeep Jain
-
Patent number: 11103502Abstract: Solid dispersions of lurasidone or a pharmaceutically acceptable salt thereof are described, as well as pharmaceutical formulations thereof, and methods for making such formulations. Preferably, the solid dispersions are prepared by hot-melt extrusion or spray-drying, and comprise lurasidone with a pharmaceutically acceptable carrier (e.g., hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), or mixtures thereof). The pharmaceutical composition may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Tmax, Cmax, AUC0-t and/or AUC0-infinity) of lurasidone, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.Type: GrantFiled: November 27, 2019Date of Patent: August 31, 2021Assignee: SLAYBACK PHARMA LLCInventors: Paras P. Jain, Ajay Kumar Singh, Praveen Kumar Subbappa, Keerthi Priya, Girish Kumar Jain, Girish G. Kore, Hanimi Reddy Bapatu, Sandeep Jain
-
Patent number: 10952981Abstract: The present invention relates to liquid pharmaceutical compositions of baclofen or a pharmaceutically acceptable salt thereof. More specifically, stable liquid pharmaceutical compositions of baclofen at concentrations of 5 mg/mL or more are provided. Preferably, the liquid pharmaceutical compositions are suitable for oral administration, and stable at pH ranges of 5-8 over a variety of storage conditions, including long-term storage for extended periods of time.Type: GrantFiled: January 24, 2020Date of Patent: March 23, 2021Assignee: SLAYBACK PHARMA LLCInventors: Sushant Omprakash Dube, Girish Kumar Jain, Venkateshwar Reddy Keesara, Josh Chandy Mathew, Purushottam Dattatraya Kulkarni, Purushottam Sakhahari Pattewar, Balakrishna Reddy Akula, Kumarswamy Ummiti
-
Publication number: 20210077485Abstract: Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Cmax, AUC0-t and/or AUC0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.Type: ApplicationFiled: November 20, 2020Publication date: March 18, 2021Applicant: SLAYBACK PHARMA LLCInventors: Paras P. Jain, Ajay Kumar Singh, Keerthi Priya, Girish Kumar Jain, Girish G. Kore, Sandeep Jain, Hanimi Reddy Bapatu
-
Patent number: 10874671Abstract: Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Cmax, AUC0-t and/or AUC0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.Type: GrantFiled: February 18, 2020Date of Patent: December 29, 2020Assignee: SLAYBACK PHARMA LLCInventors: Paras P. Jain, Ajay Kumar Singh, Keerthi Priya, Girish Kumar Jain, Girish G. Kore, Sandeep Jain, Hanimi Reddy Bapatu
-
Publication number: 20200375932Abstract: The present invention relates to liquid pharmaceutical compositions of baclofen or a pharmaceutically acceptable salt thereof. More specifically, stable liquid pharmaceutical compositions of baclofen at concentrations of 5 mg/mL or more are provided. Preferably, the liquid pharmaceutical compositions are suitable for oral administration, and stable at pH ranges of 5-8 over a variety of storage conditions, including long-term storage for extended periods of time.Type: ApplicationFiled: January 24, 2020Publication date: December 3, 2020Applicant: SLAYBACK PHARMA LLCInventors: Sushant Omprakash Dube, Girish Kumar Jain, Venkateshwar Reddy Keesara, Josh Chandy Mathew, Purushottam Dattatraya Kulkarni, Purushottam Sakhahari Pattewar, Balakrishna Reddy Akula, Kumarswamy Ummiti
-
Publication number: 20200261449Abstract: Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Cmax, AUC0-t and/or AUC0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.Type: ApplicationFiled: February 18, 2020Publication date: August 20, 2020Applicant: SLAYBACK PHARMA LLCInventors: Paras P. JAIN, Ajay Kumar SINGH, Keerthi PRIYA, Girish Kumar JAIN, Girish G. KORE, Sandeep JAIN, Hanimi Reddy BAPATU
-
Publication number: 20200237753Abstract: Delayed-release pharmaceutical compositions prepared by hot-melt extrusion are provided, where the compositions comprise an azole anti-fungal drug having poor water solubility, an enteric polymer and a non-enteric polymer, and wherein the pharmaceutical composition may be orally administered to a patient in either the fed or fasted state. Preferably, the delayed-release pharmaceutical compositions prepared by hot-melt extrusion comprise posaconazole, HPMC-AS and HPC. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (Tmax, Cmax, AUC0-t and/or AUC0-infinity) of the azole anti-fungal drug, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.Type: ApplicationFiled: May 13, 2019Publication date: July 30, 2020Applicant: SLAYBACK PHARMA LLCInventors: Paras P. Jain, Girish Kumar Jain
-
Publication number: 20200222394Abstract: Solid dispersions of lurasidone or a pharmaceutically acceptable salt thereof are described, as well as pharmaceutical formulations thereof, and methods for making such formulations. Preferably, the solid dispersions are prepared by hot-melt extrusion or spray-drying, and comprise lurasidone with a pharmaceutically acceptable carrier (e.g., hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), or mixtures thereof). The pharmaceutical composition may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Tmax, Cmax, AUC0-t and/or AUC0-infinity) of lurasidone, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.Type: ApplicationFiled: November 27, 2019Publication date: July 16, 2020Applicant: SLAYBACK PHARMA LLCInventors: Paras P. Jain, Ajay Kumar Singh, Praveen Kumar Subbappa, Keerthi Priya, Girish Kumar Jain, Girish G. Kore, Hanimi Reddy Bapatu, Sandeep Jain
-
Publication number: 20200222395Abstract: Solid dispersions of lurasidone or a pharmaceutically acceptable salt thereof are described, as well as pharmaceutical formulations thereof, and methods for making such formulations. Preferably, the solid dispersions are prepared by hot-melt extrusion or spray-drying, and comprise lurasidone with a pharmaceutically acceptable carrier (e.g., hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), or mixtures thereof). The pharmaceutical composition may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Tmax, Cmax, AUC0-t and/or AUC0-infinity) of lurasidone, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.Type: ApplicationFiled: January 28, 2020Publication date: July 16, 2020Applicant: SLAYBACK PHARMA LLCInventors: Paras P. JAIN, Ajay Kumar SINGH, Praveen Kumar SUBBAPPA, Keerthi PRIYA, Girish Kumar JAIN, Girish G. KORE, Hanimi Reddy BAPATU, Sandeep JAIN
-
Patent number: 10702520Abstract: Delayed-release pharmaceutical compositions prepared by hot-melt extrusion are provided, where the compositions comprise an azole anti-fungal drug having poor water solubility, an enteric polymer and a non-enteric polymer, and wherein the pharmaceutical composition may be orally administered to a patient in either the fed or fasted state. Preferably, the delayed-release pharmaceutical compositions prepared by hot-melt extrusion comprise posaconazole, HPMC-AS and HPC. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (Tmax, Cmax, AUC0-t and/or AUC0-infinity) of the azole anti-fungal drug, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.Type: GrantFiled: May 13, 2019Date of Patent: July 7, 2020Assignee: SLAYBACK PHARMA LLCInventors: Paras P. Jain, Girish Kumar Jain
-
Patent number: 10292994Abstract: The present invention relates to bioactive fractions and compounds from Dalbergia sissoo for the prevention or treatment of osteo-health related disorders. The present invention relates in the field of pharmaceutical composition that provides new plant extracts, their fractions and pure compound isolated from natural sources that are useful for the prevention and/or treatment of various medical indications associated with estrogen dependent or independent diseases or syndromes or disorders preferably in the prevention or treatment of estrogen dependent or independent diseases or syndromes or disorders caused in humans and animals, and achievement of peak bone mass during skeletal growth and health in humans and animals.Type: GrantFiled: April 25, 2012Date of Patent: May 21, 2019Assignee: Council of Scientific & Industrial ResearchInventors: Rakesh Maurya, Preety Dixit, Ritu Trivedi, Vikram Khedgikar, Jyoti Gautam, Avinash Kumar, Divya Singh, Shelendra Pratap Singh, Wahajuddin, Girish Kumar Jain, Naibedya Chattopadhyay
-
Patent number: 9687480Abstract: Chiral 1-(4-methylphenylmethyl)-5-oxo-{N-[(3-t-butoxycarbonyl-aminomethyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamides as inhibitors of collagen induced platelet activation and adhesion. The present invention provides chiral (2S)-1-(4-methylphenylmethyl)-5-oxo-(3S)-{N-[(3-t-butoxycarbonyl aminomethyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamide, and (2S)-1-(4-methylphenylmethyl)-5-oxo-(3R)-{N-[(3-t-butoxycarbonyl amino methyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamide of formula 6 and 7 respectively. The present invention also relates to use of these moieties as inhibitors of collagen induced platelet adhesion and aggregation mediated through collagen receptors. The present invention provides a process for preparation of chiral carboxamides of formula 6 and 7 using the process which has advantage to avoid any racemization at the a-carboxylic center, during N-alkylation. The reagent LiHMDS is used at low temperatures to furnish methyl N-(p-methylphenylmethyl)1pyroglutamate in good chiral purity.Type: GrantFiled: November 5, 2015Date of Patent: June 27, 2017Assignee: Council of Scientific & Industrial ResearchInventors: Dinesh Kumar Dikshit, Madhu Dikshit, Tanveer Irshad Siddiqui, Anil Kumar, Rabi Sankar Bhatta, Girish Kumar Jain, Manoj Kumar Barthwal, Ankita Misra, Vivek Khanna, Prem Prakash, Manish Jain, Vishal Singh, Varsha Gupta, Anil Kumar Dwivedi
-
Patent number: 9566299Abstract: The present invention relates to an oral pharmaceutical composition of aliphatic amine polymer or salts thereof comprising mixture of water and organic solvent(s) and/or less than of about 10% of plasticizing agent in the coating composition. In particular, present invention relates to a coated pharmaceutical composition of aliphatic amine polymer or salt thereof which comprises mixture of water and organic solvent(s) and less than of about 10% of plasticizing agent in coating. The invention also includes process of preparing such composition.Type: GrantFiled: February 5, 2014Date of Patent: February 14, 2017Assignee: WOCKHARDT LIMITEDInventors: Girish Kumar Jain, Venkataramana Naidu, Abdul Rehman Khan, Amar Agarwal, Srikanth Pattipati
-
Patent number: 9446032Abstract: There is provided a once-a-day therapeutically synergistic pharmaceutical dosage form for treatment of cardiovascular disorders, wherein the dosage form comprises a fixed dose combination of metoprolol in extended release form and one or more calcium channel blocker, angiotensin II receptor blocker or angiotensin converting enzyme inhibitor along with one or more rate controlling excipient.Type: GrantFiled: August 23, 2012Date of Patent: September 20, 2016Assignee: WOCKHARDT LIMITEDInventors: Mandar Madhukar Kodgule, Premchand Dalichandji Nakhat, Amit Gupta, Girish Kumar Jain
-
Patent number: 9408814Abstract: The present invention refers to a modified release pharmaceutical composition comprising desvenlafaxine or salts thereof, a release rate modifying system that controls the release of active agent(s) in both acidic and basic environments. A process of making and method of using the above-described composition is also disclosed.Type: GrantFiled: March 21, 2011Date of Patent: August 9, 2016Assignee: WOCKHARDT LIMITEDInventors: Girish Kumar Jain, Premchand Dalichandji Nakhat
-
Patent number: 9408806Abstract: The present invention relates to novel tablet dosage forms and methods of preparing these forms, which can be used for different classes of pharmaceutical active ingredients posing stability issues in a single unit system. The dosage form includes a first layer, which includes a tablet of one or more active pharmaceutical ingredients, which is inlayed in the first layer along with other pharmaceutically acceptable excipients, and a second layer that includes one or more active pharmaceutical ingredients optionally with other pharmaceutically acceptable excipients.Type: GrantFiled: September 13, 2013Date of Patent: August 9, 2016Assignee: Wockhardt LimitedInventors: Girish Kumar Jain, Ramakant Gundu, Rahul Dabre